Please click here to apply

1. Xie, SC, Metcalfe, RD, Mizutani, H, Puhalovich, T, Hanssen, E, Morton, CJ et al.. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proc Natl Acad Sci U S A. 2021;118 (39):. doi: 10.1073/pnas.2107213118. PubMed PMID:34548400 .
2. Forte, B, Ottilie, S, Plater, A, Campo, B, Dechering, KJ, Gamo, FJ et al.. Prioritization of Molecular Targets for Antimalarial Drug Discovery. ACS Infect Dis. 2021;7 (10):2764-2776. doi: 10.1021/acsinfecdis.1c00322. PubMed PMID:34523908 .
3. Summers, RL, Pasaje, CFA, Pisco, JP, Striepen, J, Luth, MR, Kumpornsin, K et al.. Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. Cell Chem Biol. 2021; :. doi: 10.1016/j.chembiol.2021.07.010. PubMed PMID:34348113 .
4. Murithi, JM, Deni, I, Pasaje, CFA, Okombo, J, Bridgford, JL, Gnädig, NF et al.. The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance. Cell Chem Biol. 2021; :. doi: 10.1016/j.chembiol.2021.06.006. PubMed PMID:34233174 .
5. Palmer, MJ, Deng, X, Watts, S, Krilov, G, Gerasyuto, A, Kokkonda, S et al.. Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series. J Med Chem. 2021;64 (9):6085-6136. doi: 10.1021/acs.jmedchem.1c00173. PubMed PMID:33876936 PubMed Central PMC8171248.

Find us social!